ELI-002
Elicio Therapeutics
['rectal', 'colorectal', 'pancreatic']
a new immunotherapy for patients with high-relapse risk (tumor marker/ctdna mrd driven) pancreatic and colorectal cancer with kras mutations has shown promising results in a phase 1 trial. the interim data will be presented at #asco23 and i can t wait to learn more! 
Georges Azzi: Medical Doctor MD. Hematology/Oncology